BioNTech Founders Exit Sparks 22% ADR Plunge, $26B Market Hit
BioNTech co-founders Ugur Sahin and Özlem Türeci will depart by year-end to form a new mRNA-focused biotech, triggering a 22% drop in its American depositary receipts. The company’s $26 billion market capitalization and plans for its first cancer therapy now face uncertainty without its founding scientific leadership.
1. Founders’ Departure Plans
Ugur Sahin and Özlem Türeci will step down by year-end to launch a new company focused on mRNA research, reallocating some of BioNTech’s technology rights to the venture in exchange for a minority stake as well as milestone and royalty payments.
2. Market Reaction and Financial Impact
The announcement triggered a 22% one-day drop in BioNTech’s American depositary receipts and put pressure on its $26 billion market capitalization, raising investor concerns about leadership stability as the company approaches its first cancer therapy approval.
3. Future mRNA Venture and Company Strategy
BioNTech plans to support the spin-off with contributions of mRNA platforms while refocusing its own operations on commercialization, speed and industrialization, but questions remain about long-term execution without its founding scientists at the helm.